A letter of intent to acquire a compounding pharmacy rarely mentions what the seller's federal and state inspection history actually found. The purchase agreement should be built around the seller's FDA inspection history, its state board of pharmacy inspection record, any sterility or potency testing failures, and whether the pharmacy's license and DEA registration can transfer to the buyer at all. Each of these is a document category a buyer can obtain and read before closing, not a risk to price in after the fact.
FDA Inspection History: 483s, Warning Letters and EIRs
A Form 483 lists the inspectional observations an FDA investigator issues at the close of an on-site inspection, before the agency decides how to classify it. A warning letter follows only after FDA's own review, and FDA posts its warning letters in a public, searchable database on fda.gov. An Establishment Inspection Report (EIR) is the investigator's own narrative of what the inspection covered; FDA's Freedom of Information Act electronic reading room posts some redacted 483s and EIRs once an inspection is closed, and a buyer can request any record not already posted through FOIA. A buyer should request all three for the target facility and compare them to the seller's written response. For a pharmacy already managing an open warning letter, FDA Escalation After a Warning Letter: Injunction, Seizure and Consent Decree describes what happens next, a track record the buyer inherits.
State Board Inspection and Licensure Transfer
State boards of pharmacy run their own compounding inspections independent of FDA, and a board's inspection and disciplinary file on the target pharmacy is a second record set a buyer needs before closing. Compounding inspections can review recordkeeping tied to cGMP-adjacent standards: garbing and environmental controls consistent with USP 797/800, equipment calibration, and the pharmacy's 503A/503B status and master formulation records. Board records, including prior citations, consent orders, and license probation, are obtainable directly from the board as a public record, subject to the state's public records procedure. A pharmacy under a consent order or probation carries conditions attached to the license itself, and a buyer who skips the order inherits them.
Whether that license can transfer to a new owner is a state-by-state question. Texas Pharmacy Act Section 560.101, for example, makes the pharmacy's existing license non-transferable, so a change of ownership requires the buyer to obtain a new pharmacy license in its own name rather than step into the seller's. Once the new license issues, the pharmacy must separately obtain a new DEA registration: DEA registration is not transferable to another person without the agency's written consent, so a change of ownership does not carry the seller's registration to the buyer.
Sterility and Potency Failure History
Sterility and potency testing failures are the compounding-specific risk a standard pharmacy diligence checklist tends to miss. A pattern of failed environmental monitoring results, out-of-specification potency assays, or beyond-use date extensions applied without supporting stability data can produce an FDA warning letter, board discipline, or a recall. Environmental Monitoring Programs Under Inspection covers what an auditor expects that program to document; the diligence request should cover that ground as well: the beyond-use date extensions the pharmacy has applied, a practice Extending Beyond-Use Dates: What Justifies It explains, and the lab reports behind any recall.
The purchase agreement is the only place this risk can still be allocated. After closing, it is inherited.
Allocating Risk Before Closing
The same closing mechanic applies to two conditions that attach to the pharmacy rather than to its current owner: the pharmacy's DEA registration status and any PBM audit the seller has open at signing. Both belong in the purchase agreement's representations, escrow, and indemnification provisions negotiated before signing, not in a conversation with counsel after the deal has closed.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
Why Early Legal Counsel Is Critical
It is critical that buyers and sellers of compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry affecting the pharmacy, whether before or after closing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance represents buyers and sellers in compounding pharmacy acquisitions, FDA inspection responses, and state board compounding matters nationwide. Our attorneys review a target pharmacy's 483s, warning letters, EIRs, and board inspection file alongside the purchase agreement, so the risk the diligence uncovers is allocated in the deal rather than left for the buyer to absorb after closing. If you are buying or selling a compounding pharmacy, contact our compounding pharmacy attorneys for a free, confidential consultation.
